Seglupac 7mg

Seglupac 7mg

This medicine is prescription only medicine (POM ) and required under medical supervision .

ဤဆေးသည် POM ဆေးအုပ်စုတွင်ပါဝင်သောကြောင့် ဆရာဝန်ညွှန်ကြားချက်အတိုင်းသာ သုံးစွဲသင့်ပါသည် ။

Description

Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. Semaglutide reduces blood glucose through a mechanism where it stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner. Thus, when blood glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase.

Indications

SEGLUPAC is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitations of Use • Not for treatment of type 1 diabetes mellitus.

Dosage

• Starting Dosage (Initiation Phase) (Days 1 to 30): The recommended starting dosage is 3 mg orally once daily (this dosage is not effective for glycemic control).

• Escalation and Maintenance Dosage (Days 31 and beyond):

o Days 31 to 60: Increase the dosage to 7 mg orally once daily.

o On Day 61 or thereafter, if:

▪ No additional glycemic control is needed, maintain the dosage at 7 mg orally once daily.

▪ Additional glycemic control is needed, increase the dosage to 14 mg orally once daily.